QIAGEN Raises Offer for Cellestis
QIAGEN will acquire the shares of Cellestis’s cofounders at the original offer price. QIAGEN has also finalized its agreement to acquire 61% of Ipsogen (see IBO 6/15/11). This transaction is expected to be completed this month.
Venlo, the Netherlands and Melbourne, Australia 7/11/11— QIAGEN has increased its offer to acquire diagnostics maker Cellestis (see IBO 4/15/11). QIAGEN increased the offer price by 7% to AUD 3.80 ($3.96 =AUD 0.96 = $1) per share for a value of $374 million. QIAGEN stated that this would be its final offer absent a competing proposal. Cellestis has also proposed a special divide of up to AUD $0.07 ($0.07), which would correspondingly reduce the cash offer. The deal is expected to close in August pending shareholder approval.
